News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Sandoz opens advanced high-volume drug substance manufacturing centre in Lendava, significantly strengthening in-house capacity and flexibility across leading European biosimilar network
Sandoz opens advanced high-volume biosimilar drug substance manufacturing centre in Lendava, Slovenia, strengthening Europe's biologic manufacturing base and supply chain resilience for key medicines -
-
-
COMMUNIQUÉ DE PRESSE
Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines
Sandoz announces collaboration with mAbxience to expand patient access to life-enhancing biosimilar medicines in a licensing agreement for emicizumab biosimilar worth USD 5.7 billion -